• Infectex, of Moscow, a biotech firm in the Maxwell Biotech Venture Fund's portfolio, said it enrolled the first patients in a Phase II/III trial of diamine compound SQ109 for multidrug-resistant tuberculosis. The two-year trial is expected to support regulatory approval in Russia and the Commonwealth of Independent States. It is designed to compare the effects of an optimized background drug regimen alone to an optimized background regimen plus SQ109. Infectex licensed rights to the drug from Sequella Inc., of Rockville, Md.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter